2016-05-012024-05-13https://scholars.lib.ntu.edu.tw/handle/123456789/649882摘要：由於基因體研究技術及生物資訊學的發展，加速生物檢體及疾病相關資料的需求，建立生 物檢體庫及海量數據已成為生命科學研究、轉譯研究、臨床研究，及臨床藥物開發和應用的重 要基石。本計晝第三年度預計10家醫學中心参加，用以募集北、中及南部不同社經、族群和生活 型態的婦癌病患。經計晝前二年實際執行結果計晝總目標修正為，三年募集580位原位及侵襲 性子宮頸癌、1450位子宮體癌、及1380卵巢癌病患，收集生物檢體（組織、血液、及腹水）、追 蹤病理診斷、治療及預後資料，並利用問卷訪視收集癌症相關危險因子，生活品質、睡眠及活動量表。參與本計晝的各醫院遵循標準程序進行檢體採集及保存，生物檢體儲存於各醫院，疾病相 關資料由電腦傳輸集中保存於中央資料庫。檢體和資料開放各界使用，使用者委員會審核生物 資料的申請案，並監督使用的正確及公平性。本研究由多家醫院共同參與合作，彼此緊密聯繫，溝通協調迅速，其組織架構將來可延伸 為各類研究的平台，現有的檢體收案系統及資訊系統將來可運用於臨床研究。另外利用計晝既 有的合作基礎可有效推展各類研究合作案，以群組之力量拓展與各界合作的管道，藉以協助藥 物研發的各階段研究，支持NRPB各類型計晝，推動生物科技產業發展。<br> Abstract: Advances of emerging technologies in genomic researches have accelerated the development of cancer research, and have innovated the strategies of disease prediction, diagnoses, and treatment. Therefore, having access to a wide collection of biospecimens coupled with epidemiological or clinical data is essential for genomic researches. The mission of the Taiwan Gynecologic Cancer (TGC) Network is to serve as a technology platform providing high quality biosamples and information to enhance the innovative biomedical and translation research.In the 3rd project year, he TGC Network will recruit 10 participating hospitals in northern, central and southern Taiwan, to collect the representative patients of gynecologic cancer. The TGC Network collects various of biosamples including tissues, plasma, peripheral blood mononucleated cells, and ascites from patients with invasive cervical cancer/carcinoma in situ, uterine cancer, ovarian cancer. Disease relevant data includes diagnosis, disease status, cancer cell types and stages, medical history, family history of cancers and chronic diseases, menstrual history, hormone use, physical activity, quality of life, and sleep quality are collected. The objective of this project is to recruit 580 cervical, 1450 uterine, and 1380 ovarian cancer patients.The TGC Network plays an essential role to tie chains of drug discovery together to support NRPB programs and pharmaceutical industries. The representative biosamples and comprehensive disease relevant data are able to discover previous unseen patterns in both pre-clinical and clinical research. The integration of biosample and data helps elucidate the link between genotype and phenotype, and control the confounding factors to construct valid studies. Additionally, biosamples with high quantity of biosamples in biobank shortens the time to collect statistically meaningful sample size. For clinical trial, the comprehensive disease relevant data in the network help make an accurate trial strategy. Additionally, in the future the infrastructure and the connection of the network can work as a management platform to facilitate multicenter clinical trials.生物資料庫卵巢癌子宮頸癌子宮體癌子宮内膜癌基因體研究轉譯醫學生 活品質癌症危險因子biobankcervical canceruterine cancerovarian cancergenomic studytranslational medicinequality of lifecancer risk factors